A detailed history of Black Rock Inc. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 12,308,002 shares of RVMD stock, worth $472 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,308,002
Previous 12,954,314 4.99%
Holding current value
$472 Million
Previous $372 Million 6.77%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$26.56 - $33.55 $17.2 Million - $21.7 Million
-646,312 Reduced 4.99%
12,308,002 $397 Million
Q4 2023

Feb 13, 2024

BUY
$18.35 - $34.12 $74.9 Million - $139 Million
4,082,900 Added 46.02%
12,954,314 $372 Million
Q3 2023

Nov 13, 2023

BUY
$25.17 - $35.05 $15.4 Million - $21.5 Million
613,798 Added 7.43%
8,871,414 $246 Million
Q2 2023

Aug 11, 2023

BUY
$20.28 - $27.0 $16.1 Million - $21.4 Million
791,842 Added 10.61%
8,257,616 $221 Million
Q1 2023

May 12, 2023

BUY
$20.76 - $30.09 $18.5 Million - $26.8 Million
889,828 Added 13.53%
7,465,774 $162 Million
Q4 2022

Feb 13, 2023

BUY
$17.68 - $25.53 $3.93 Million - $5.68 Million
222,487 Added 3.5%
6,575,946 $157 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $16.6 Million - $24.7 Million
949,655 Added 17.57%
6,353,459 $125 Million
Q2 2022

Aug 12, 2022

BUY
$14.54 - $27.17 $923,522 - $1.73 Million
63,516 Added 1.19%
5,403,804 $105 Million
Q1 2022

May 12, 2022

SELL
$17.31 - $26.4 $2.34 Million - $3.56 Million
-134,931 Reduced 2.46%
5,340,288 $136 Million
Q4 2021

Feb 10, 2022

BUY
$24.35 - $33.7 $8.99 Million - $12.4 Million
369,181 Added 7.23%
5,475,219 $138 Million
Q3 2021

Nov 09, 2021

BUY
$23.95 - $33.41 $6.9 Million - $9.62 Million
287,908 Added 5.98%
5,106,038 $140 Million
Q2 2021

Aug 11, 2021

BUY
$29.0 - $47.44 $140 Million - $229 Million
4,818,130 New
4,818,130 $153 Million

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.36B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.